Abstract
The paper by Brynskov et al. (Sept. 28 issue)1 is clearly important as the first published randomized, controlled trial of oral cyclosporine in Crohn's disease. The editorial by Sachar2 asks whether this is a step backward or a leap forward. We do not believe that this question has been resolved by the paper.